LM 168
Alternative Names: LM-168Latest Information Update: 04 Jul 2025
At a glance
- Originator LaNova Medicines Limited
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 25 May 2025 Pharmacodynamics and adverse events data from preclinical trials in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research(AACR-2025)
- 25 Apr 2025 Preclinical trials in Solid tumours in China (Parenteral)
- 31 Mar 2025 LaNova Medicines plans a phase I/II trial for Solid tumours (Late-stage disease, Combination therapy, Monotherapy, Second-line therapy or greater, Recurrent) in Australia (Parenteral) in March 2025 (NCT06868199)